Infectious Diseases News and Research

RSS

Study examines transmission-risk assessment metrics for infectious diseases in indoor spaces

A recent study published in the journal Engineering delves into the complex world of assessing the transmission risk of infectious diseases in indoor spaces.

2 Mar 2025

Widespread E. coli contamination found in Egyptian dairy

No one should have to fear food poisoning every time they eat or drink, but the reality, even in the 21st century, is that risks remain. An Osaka Metropolitan University-led Egypt-Japan research team found E. coli prevalent in over 25% of popular milk and dairy products in Egypt.

28 Feb 2025

Elderly populations: Global trends in the healthy aging market

To be decided by the editor

From Atlantia Clinical Trials 28 Feb 2025

Hospitalized COVID patients face long-term risks

A nationwide study has revealed that survivors of COVID-19 hospitalization face an increased risk of death or organ-related disorders for up to two-and-a-half years after discharge.

28 Feb 2025

New deep-learning framework improves spatial transcriptomics analysis

Biological tissues are made up of different cell types arranged in specific patterns, which are essential to their proper functioning.

27 Feb 2025

Study highlights increase in VZV-induced CNS infections and dementia risk

Researchers from Fujita Health University, Japan, observed a rise in adult central nervous system (CNS) infections, primarily aseptic meningitis caused by the varicella zoster virus (VZV), post-2019. The researchers highlighted the potential of zoster vaccination to reduce CNS infections.

27 Feb 2025

Scientists pioneer fecal transplant capsules to enhance pancreatic cancer treatment

Scientists at Lawson Research Institute (Lawson) of St. Joseph's Health Care London and London Health Sciences Centre Research Institute (LHSCRI) are the first in the world to study fecal transplants using capsules containing microbes from the gut of healthy volunteers to improve the response of patients with advanced pancreatic cancer to chemotherapy.

26 Feb 2025

Insilico Medicine reaches preclinical milestone in MASH drug discovery

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently achieved preclinical milestone in its collaboration with Therasid Bioscience, a South Korean based biotechnology company focuses on developing innovative first-in-class drugs for treatment for metabolic dysfunction-associated steatohepatitis (MASH).

25 Feb 2025

Can AI predict the next pandemic? A new study says yes

Researchers explore how artificial intelligence is transforming infectious disease modeling

25 Feb 2025

T cells play key role in protecting children from severe dengue

Children who experience multiple cases of dengue virus develop an army of dengue-fighting T cells, according to a new study led by scientists at La Jolla Institute for Immunology (LJI).

24 Feb 2025

Zika virus hijacks tunneling mechanism to infect placental cells

Infection with Zika virus in pregnancy can lead to neurological disorders, fetal abnormalities and fetal death. Until now, how the virus manages to cross the placenta, which nurtures the developing fetus and forms a strong barrier against microbes and chemicals that could harm the fetus, has not been clear.

22 Feb 2025

AI-driven discovery unveils TNIK inhibition as anti-aging strategy

A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy.

22 Feb 2025

New human antibody shows promise for Ebola virus treatment

New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus therapeutics.

21 Feb 2025

Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.

21 Feb 2025